Abstract:Background: Current methods for assessing the response of lung cancer patients to therapy (e.g. RECIST criteria) lack consideration for mixed response (MR) where some lesions increase while others decrease simultaneously. MR poses a challenge in deciding the continuation of therapy. Understanding the clinical implications of MR on patient prognosis within radiographic response categories is crucial for establishing effective treatment strategies for NSCLC. Methods: This study analyzed 177 NSCLC patients with ≥2 lesions receiving first-line systemic treatment with immunotherapy. Clinical response was evaluated by RECIST v1.1 and immune-related RECIST (irRECIST). MR was defined as the simultaneous presence of ≥1 lesion increase and ≥1 lesion decrease during therapy. Two different definitions of MR were utilized. Definition-A (MR-A): the simultaneous presence of one or more lesions increasing ≥5mm and one or more lesions decreasing ≥5mm during therapy (Δ [baseline - first follow-up] ≥ 5 mm); and Definition-B (MR-B): the simultaneous presence of one or more lesions increasing >1mm and one or more lesions decreasing >1mm during therapy (any Δ [baseline - first follow-up]). Subgroup analysis was conducted using 94 patients with only intrathoracic lesions. Results: Among the 177 patients, tumor responses based on RECIST were 3 CR (1.7%),42 PR (23.7%), 87 SD (49.2%), and 45 PD (25.4%). Based on irRECIST, responses were 3 CR (1.7%), 46 PR (26.0%), 89 SD (50.3%), and 39 PD (22.0%). MR-A and MR-B occurred in 19.8% (n=35) and 45.2% (n=80) of cases, respectively. In the irRECIST PD group, MR-A demonstrated significantly different median progression-free survival (mPFS) and median overall survival (mOS) compared to non-MR-A (p<0.020, p<0.005, respectively). The mPFS for MR-A group was 1.4 months (range 0.5-52.9) and non-MR-A group was 5.5 months (range 0.2-97.2) with the hazard ratio being 2.91 (95% CI 1.13-7.51). The mOS for MR-A and non-MR-A groups were 4.8 months (range 0.7-61.5) and 11.8 months (range 0.2-97.2), respectively, hazard ratio 4.87 (95% CI 1.43-16.56). No other significant results were found for other RECIST and irRECIST categories. Subgroup analysis of only intrathoracic lesion patients revealed no statistically significant results. Conclusion: Contrary to our hypothesis, MR did not modify prognosis within the RECIST or irRECIST category. MR-A or MR-B in the RECIST or irRECIST PD group did not show a better prognosis, indicating the complexity of mixed responses in NSCLC patients treated with immunotherapy. Further research with larger cohorts are warranted. Citation Format: Seyoung Lee, Taegyu Um, Jeeyeon Lee, Peter Haseok Kim, Monica Yadav, Maria J. Chuchuca, Liam Il-Young Chung, Young Kwang Chae. Clinical implications of mixed response on prognosis of non-small cell lung cancer (NSCLC) patients treated with Immunotherapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 3844.

Histological Assessment and Interobserver Agreement in Major Pathologic Response for Non-Small Cell Lung Cancer with Neoadjuvant Therapy

Radiomics Model Based on Intratumoral and Peritumoral Features for Predicting Major Pathological Response in Non-Small Cell Lung Cancer Receiving Neoadjuvant Immunochemotherapy

Major Pathological Response Exhibited Distinct Prognostic Significance for Lung Adenocarcinoma Post Different Modalities of Neoadjuvant Therapy.

Comparison of different criteria for estimating major pathological response in resectable non-small cell lung cancer treated with neoadjuvant chemoimmunotherapy

Clinical factors and major pathological response after neoadjuvant chemoimmunotherapy in potentially resectable lung squamous cell carcinoma

Major pathologic response assessment and clinical significance of metastatic lymph nodes after neoadjuvant therapy for non-small cell lung cancer

Does Major Pathological Response after Neoadjuvant Immunotherapy in Resectable Nonsmall-Cell Lung Cancers Predict Prognosis? A Systematic Review and Meta-Analysis

A prognostic score for non-small cell lung cancer resected after neoadjuvant therapy in comparison with the tumor-node-metastases classification and major pathological response

Different pathological response and histological features following neoadjuvant chemotherapy or chemo-immunotherapy in resected non-small cell lung cancer

Association between pathologic response and survival after neoadjuvant therapy in lung cancer

Tumor Response Assessment by Measuring the Single Largest Lesion Per Organ in Advanced Non-Small Cell Lung Cancer Patients Treated with PD-1/PD-L1 Inhibitor.

The Predictive Value of 18F-FDG PET/CT Combined with Inflammatory Index for Major Pathological Reactions in Resectable NSCLC Receiving Neoadjuvant Immunochemotherapy.

Is Response Evaluation Criteria in Solid Tumors (RECIST) Effective in Patient Selection for Radical Resection after Neoadjuvant Immunotherapy with Advanced NSCLC?

Easily applicable predictive score for MPR based on parameters before neoadjuvant chemoimmunotherapy in operable NSCLC: a single-center, ambispective, observational study

Serologic, radiographic, and tissue-based markers associated with major pathologic response after treatment with neoadjuvant immunotherapy in patients with resectable hepatocellular carcinoma.

Abstract 3844: Clinical implications of mixed response on prognosis of non-small cell lung cancer (NSCLC) patients treated with Immunotherapy

Evaluation of Combined Pathological Responses in Primary Tumor and Lymph Nodes Following Neoadjuvant Chemoimmunotherapy in Non-Small Cell Lung Cancer.

Evaluation of MPR and pCR as surrogate endpoints for survival in randomized controlled trials of neoadjuvant immune checkpoint blockade in resectable in non-small cell lung cancer.

Radiological response as a predictor of pathological response to combined tyrosine kinase inhibitor (TKI) and anti-PD-1 antibodies in hepatocellular carcinoma (HCC).

Pathological assessment of non-small cell lung cancer resection specimens after neoadjuvant therapy

Dynamic F-18-FDG PET/CT can predict the major pathological response to neoadjuvant immunotherapy in non-small cell lung cancer